By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Quigley Pharma Inc. 

Kells Building
621 N. Shady Retreat Road

P.O. Box 2071
Doylestown  Pennsylvania  18901  U.S.A.
Phone: 267-880-1100 Fax: 267-880-1153



Company News
Pfizer Inc. (PFE) Unit Quigley Pharma Inc. (QGLY) To Exit Ch. 11 With $265M Asbestos Settlement 3/23/2011 6:50:16 AM
Quigley Corporation (QGLY) Announces Final Results of Quigley Pharma Inc. (QGLY)'s Phase IIb Study 7/22/2009 8:34:28 AM
Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma Inc. (QGLY), From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation 5/19/2009 11:28:24 AM
Quigley Pharma Inc. (QGLY) Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter 11/12/2008 8:27:23 AM
Quigley Pharma Inc. (QGLY) Evaluates Regulatory and Market Opportunities for Anti-Inflammatory / Cytokine Modifying Compound 8/1/2007 11:58:28 AM
Quigley Pharma Inc. (QGLY) Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients 7/30/2007 8:59:29 AM
Quigley Pharma Inc. (QGLY) Granted Patent For Prophylactic And Anti-Transmissivity Uses Of An Anti-Microbial Composition 2/12/2007 12:35:33 PM
Quigley Pharma Inc. (QGLY) Broad Spectrum Anti-Viral QR-441(a) Shown To Be Effective Against Two Problematic Pathogens To The Poultry Industry 1/8/2007 3:06:44 PM
Quigley Pharma Inc. (QGLY)'s QR-333 Phase IIb Clinical Study Has Commenced; Drug Product And Clinical Trial Sites Prepared For Phase IIb Study Of Lead Drug Candidate 11/20/2006 9:51:51 AM
Quigley Pharma Inc. (QGLY)'s Radioprotective Compound QR-336 Shown To Be Most Effective In Oral And Subcutaneous Injection Dose Forms in Animal Model Study 10/3/2006 10:59:46 AM